Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | MMP16 | P51512 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925763 | 0.90 | HSD11B1 (0.37) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1926282 | 0.90 | HSD11B1 (0.37) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1948915 | 0.86 | HSD11B1 (0.39) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1948966 | 0.84 | AAK1 (0.41) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1949385 | 0.81 | NPSR1 (0.36) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1927529 | 0.80 | HSD11B1 (0.38) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1952111 | 0.80 | MEN1 (0.38) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL1950523 | 0.78 | HSD11B1 (0.36) | HSD11B1MMP13NPSR1KMT2A | |
| SCHEMBL2028960 | 0.78 | TP53 (0.38) | HSD11B1KMT2A | |
| SCHEMBL1925338 | 0.78 | NPSR1 (0.34) | HSD11B1MMP13NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | claimed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2509941-A2 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | The Johns Hopkins University (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2509942-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | Johns Hopkins University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071951-A2 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | HSD11B1 323/4885MMP13 1620/4885ADAMTS4 1158/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | HSD11B1 342/4885MMP13 2000/4885ADAMTS4 2269/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | HSD11B1 323/4885MMP13 1620/4885ADAMTS4 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.